Sphera Funds Management LTD.
Sphera Funds Management LTD. is an exempt reporting adviser based in Tel Aviv, Israel that reports managing 1 hedge fund on Form ADV. Its private funds, of all types, hold $849.7 million in gross assets. Its disclosed U.S. stock holdings returned an estimated +31.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +81.9% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- —Form ADV Item 5.F
- Gross assets of private funds
- $849.7 millionAll private fund types, Form ADV
- Hedge funds managed
- 11 private funds in total
- Employees
- —Form ADV Item 5.A
- Registration
- Exempt reporting adviserCRD 312614
- Latest Form ADV
- 03/17/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +16.3% | +14.8% |
| Q1 2026 | +12.9% | -4.6% |
| Q4 2025 | +23.6% | +2.4% |
| Q3 2025 | +28.9% | +7.8% |
| Q2 2025 | +8.1% | +10.4% |
| Q1 2025 | -15.0% | -4.5% |
| Q4 2024 | -8.1% | +2.1% |
| Q3 2024 | +2.9% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 100 share positions ($660,392,803) reported by Sphera Funds Management LTD. on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Mineralys Therapeutics Inc5.03%
- Teva Pharmaceutical Inds LTD4.92%
- Alnylam Pharmaceuticals Inc4.51%
- Cytokinetics Inc3.61%
- Ishares TR3.19%
- Bridgebio Pharma Inc3.11%
- Tower Semiconductor LTD2.92%
- Syndax Pharmaceuticals Inc2.87%
- Biomarin Pharmaceutical Inc2.66%
- Biogen Inc2.59%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Mineralys Therapeutics Inc | $33,218,367 | 5.03% | 1,321,861 | -10.08% |
| Teva Pharmaceutical Inds LTD | $32,522,767 | 4.92% | 821,282 | New |
| Alnylam Pharmaceuticals Inc | $29,757,337 | 4.51% | 120,602 | +1,016.69% |
| Cytokinetics Inc | $23,852,631 | 3.61% | 361,897 | +64.51% |
| Ishares TR | $21,039,680 | 3.19% | 37,000 | New |
| Bridgebio Pharma Inc | $20,510,979 | 3.11% | 311,717 | +27.05% |
| Tower Semiconductor LTD | $19,272,418 | 2.92% | 84,740 | -21.73% |
| Syndax Pharmaceuticals Inc | $18,936,826 | 2.87% | 1,007,278 | -0.72% |
| Biomarin Pharmaceutical Inc | $17,594,760 | 2.66% | 293,246 | -10.75% |
| Biogen Inc | $17,113,346 | 2.59% | 75,763 | -21.59% |
| Cogent Biosciences Inc | $16,059,311 | 2.43% | 501,540 | +9.19% |
| Nova LTD | $15,039,749 | 2.28% | 39,044 | +55.13% |
| Madrigal Pharmaceuticals Inc | $12,999,648 | 1.97% | 25,795 | +48.09% |
| Meta Platforms Inc | $11,747,916 | 1.78% | 16,200 | New |
| Immatics N.V | $11,455,547 | 1.73% | 1,304,732 | +81.20% |
| Sanofi SA | $11,112,103 | 1.68% | 269,515 | Unchanged |
| Astrazeneca PLC | $11,065,539 | 1.68% | 68,530 | +9.60% |
| Maze Therapeutics Inc | $9,955,708 | 1.51% | 366,288 | -12.28% |
| Eli Lilly & Co | $9,302,923 | 1.41% | 8,040 | Unchanged |
| Kla Corp | $8,814,735 | 1.33% | 45,220 | New |
| Lam Research Corp | $8,508,409 | 1.29% | 25,900 | +40.23% |
| Pfizer Inc | $8,156,720 | 1.24% | 286,000 | Unchanged |
| Ideaya Biosciences Inc | $8,122,295 | 1.23% | 211,408 | +7.64% |
| Rhythm Pharmaceuticals Inc | $7,655,286 | 1.16% | 80,400 | Unchanged |
| Johnson & Johnson | $7,632,719 | 1.16% | 28,831 | Unchanged |
| Tango Therapeutics Inc | $7,591,038 | 1.15% | 304,250 | +19.67% |
| Disc Medicine Inc | $7,510,749 | 1.14% | 114,738 | +80.58% |
| Vor Biopharma Inc | $7,315,596 | 1.11% | 383,417 | -7.92% |
| Applied Matls Inc | $7,312,734 | 1.11% | 14,300 | +29.53% |
| Abivax SA | $7,299,358 | 1.11% | 73,716 | New |
| Pharvaris N V | $7,286,084 | 1.10% | 229,700 | New |
| Camtek LTD | $7,265,700 | 1.10% | 46,800 | New |
| Merck & Co Inc | $7,062,066 | 1.07% | 48,600 | -17.06% |
| Nuvectis Pharma Inc | $6,830,736 | 1.03% | 323,425 | -15.54% |
| Novartis AG | $6,412,843 | 0.97% | 45,000 | -10.00% |
| Abbvie Inc | $5,821,947 | 0.88% | 22,256 | -26.44% |
| First Tracks Biotherapeutics | $5,678,799 | 0.86% | 160,237 | +474.82% |
| Trevi Therapeutics Inc | $5,517,911 | 0.84% | 385,329 | -22.78% |
| Satellos Bioscience Inc | $5,428,865 | 0.82% | 638,690 | -2.13% |
| Annexon Inc | $5,171,966 | 0.78% | 1,222,687 | New |
| Ultragenyx Pharmaceutical In | $5,089,804 | 0.77% | 338,643 | -42.46% |
| Climb Bio Inc | $4,780,088 | 0.72% | 416,747 | -13.85% |
| Cybin Inc | $4,770,376 | 0.72% | 388,151 | -76.05% |
| Oric Pharmaceuticals Inc | $4,706,189 | 0.71% | 349,383 | -53.60% |
| Revolution Medicines Inc | $4,597,824 | 0.70% | 22,400 | Unchanged |
| Novo-nordisk A S | $4,574,865 | 0.69% | 120,677 | Unchanged |
| Enliven Therapeutics Inc | $4,573,228 | 0.69% | 99,765 | -11.53% |
| Tenax Therapeutics Inc | $4,376,665 | 0.66% | 2,315,696 | +1,826.54% |
| Tectonic Therapeutic Inc | $4,365,431 | 0.66% | 187,438 | New |
| GSK PLC | $4,335,300 | 0.66% | 90,000 | -11.76% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 22 new positions, 19 sold out, 30 increased, 34 reduced and 14 unchanged.
Number of positions (a count, not dollars)
- New positions22
- Increased30
- Unchanged14
- Reduced34
- Sold out19
New positions
| Stock | Value | Shares |
|---|---|---|
| Teva Pharmaceutical Inds LTD | $32,522,767 | 821,282 |
| Ishares TR | $21,039,680 | 37,000 |
| Meta Platforms Inc | $11,747,916 | 16,200 |
| Kla Corp | $8,814,735 | 45,220 |
| Abivax SA | $7,299,358 | 73,716 |
| Pharvaris N V | $7,286,084 | 229,700 |
| Camtek LTD | $7,265,700 | 46,800 |
| Annexon Inc | $5,171,966 | 1,222,687 |
| Tectonic Therapeutic Inc | $4,365,431 | 187,438 |
| Crescent Biopharma Inc. | $4,081,086 | 279,718 |
| Adlai Nortye LTD | $3,770,624 | 235,664 |
| Q32 Bio Inc | $3,712,180 | 448,873 |
| Rapport Therapeutics Inc | $3,360,000 | 100,000 |
| Latigo Biotherapeutics Inc | $3,208,404 | 192,120 |
| Applied Optoelectronics Inc | $3,197,165 | 32,210 |
| Pyxis Oncology Inc | $1,605,370 | 689,000 |
| Erasca Inc | $1,600,872 | 109,200 |
| Jade Biosciences Inc | $1,482,682 | 105,529 |
| Intellia Therapeutics Inc | $1,088,415 | 90,250 |
| Quoin Pharmaceuticals LTD | $1,077,227 | 236,234 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Teva Pharmaceutical Inds LTD | $50,822,778 | 1,500,082 |
| Insmed Inc | $12,666,456 | 118,800 |
| Solaredge Technologies Inc | $7,747,190 | 4,000,000 |
| Xenon Pharmaceuticals Inc | $6,337,800 | 105,000 |
| Zenas Biopharma Inc | $5,858,567 | 230,834 |
| Forte Biosciences Inc | $5,305,976 | 249,693 |
| Vistra Corp | $4,671,654 | 29,450 |
| Talen Energy Corp | $4,662,995 | 12,135 |
| Global X FDS | $4,454,766 | 195,900 |
| Biocryst Pharmaceuticals Inc | $4,220,510 | 422,051 |
| Generate Biomedicines Inc | $4,133,150 | 245,000 |
| Kodiak Sciences Inc | $3,186,772 | 81,796 |
| Ormat Technologies Inc | $3,050,834 | 28,015 |
| Biohaven LTD | $2,446,823 | 164,437 |
| Constellation Energy Corp | $2,446,445 | 9,850 |
| Verastem Inc | $2,416,654 | 632,632 |
| Structure Therapeutics Inc | $1,534,962 | 28,600 |
| Curis Inc | $1,033,717 | 98,996 |
| Shattuck Labs Inc | $600,039 | 86,461 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Alnylam Pharmaceuticals Inc | +109,802 | +1,016.69% | $29,757,337 | 120,602 |
| Cytokinetics Inc | +141,910 | +64.51% | $23,852,631 | 361,897 |
| Nova LTD | +13,875 | +55.13% | $15,039,749 | 39,044 |
| Immatics N.V | +584,675 | +81.20% | $11,455,547 | 1,304,732 |
| First Tracks Biotherapeutics | +132,361 | +474.82% | $5,678,799 | 160,237 |
| Bridgebio Pharma Inc | +66,371 | +27.05% | $20,510,979 | 311,717 |
| Madrigal Pharmaceuticals Inc | +8,376 | +48.09% | $12,999,648 | 25,795 |
| Tenax Therapeutics Inc | +2,195,496 | +1,826.54% | $4,376,665 | 2,315,696 |
| Disc Medicine Inc | +51,200 | +80.58% | $7,510,749 | 114,738 |
| Evommune Inc | +368,000 | +1,626.02% | $3,226,620 | 390,632 |
| Lam Research Corp | +7,430 | +40.23% | $8,508,409 | 25,900 |
| Applied Matls Inc | +3,260 | +29.53% | $7,312,734 | 14,300 |
| Cogent Biosciences Inc | +42,200 | +9.19% | $16,059,311 | 501,540 |
| Tango Therapeutics Inc | +50,000 | +19.67% | $7,591,038 | 304,250 |
| Astrazeneca PLC | +6,000 | +9.60% | $11,065,539 | 68,530 |
| Immix Biopharma Inc | +85,800 | +31.78% | $3,702,099 | 355,800 |
| Ovid Therapeutics Inc | +247,000 | +18.26% | $3,984,000 | 1,600,000 |
| Corvus Pharmaceuticals Inc | +53,200 | +21.72% | $3,434,815 | 298,161 |
| Ideaya Biosciences Inc | +15,000 | +7.64% | $8,122,295 | 211,408 |
| Upstream Bio Inc | +106,131 | +48.31% | $1,717,129 | 325,831 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Cybin Inc | -1,232,602 | -76.05% | $4,770,376 | 388,151 |
| Oric Pharmaceuticals Inc | -403,600 | -53.60% | $4,706,189 | 349,383 |
| Tower Semiconductor LTD | -23,525 | -21.73% | $19,272,418 | 84,740 |
| Celldex Therapeutics Inc New | -149,772 | -62.18% | $2,952,421 | 91,096 |
| Biogen Inc | -20,863 | -21.59% | $17,113,346 | 75,763 |
| Ultragenyx Pharmaceutical In | -249,851 | -42.46% | $5,089,804 | 338,643 |
| Mineralys Therapeutics Inc | -148,110 | -10.08% | $33,218,367 | 1,321,861 |
| Harmony Biosciences Hldgs In | -80,900 | -45.79% | $3,759,655 | 95,763 |
| Acadia Pharmaceuticals Inc | -154,447 | -43.32% | $4,072,053 | 202,087 |
| Biomarin Pharmaceutical Inc | -35,304 | -10.75% | $17,594,760 | 293,246 |
| Abbvie Inc | -8,000 | -26.44% | $5,821,947 | 22,256 |
| Cytomx Therapeutics Inc. | -753,605 | -85.73% | $341,074 | 125,395 |
| Trevi Therapeutics Inc | -113,700 | -22.78% | $5,517,911 | 385,329 |
| Merck & Co Inc | -10,000 | -17.06% | $7,062,066 | 48,600 |
| Maze Therapeutics Inc | -51,276 | -12.28% | $9,955,708 | 366,288 |
| Nuvectis Pharma Inc | -59,520 | -15.54% | $6,830,736 | 323,425 |
| Alpha Cognition Inc | -130,262 | -23.87% | $3,739,986 | 415,554 |
| Scholar Rock Hldg Corp | -22,000 | -23.34% | $3,491,845 | 72,265 |
| Skye Bioscience Inc | -591,664 | -87.15% | $140,494 | 87,264 |
| Climb Bio Inc | -67,000 | -13.85% | $4,780,088 | 416,747 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Tenax Therapeutics, Inc. | 13G amendment | 7.09% | 2,663,296 | Oct 13, 2026 | SEC.gov ↗ |
| ProMIS Neurosciences Inc. | 13G amendment | 7.78% | — | Feb 5, 2026 | SEC.gov ↗ |
| Outlook Therapeutics, Inc. | 13G amendment | 4.69% | 3,153,856 | Feb 5, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Feb 5, 2026, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (4)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (1)
As reported in the adviser's Form ADV filed Mar 6, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures